[Skip to Navigation]
Comment & Response
January 2018

Simulation Models of Therapy Intensification in Lipid-Lowering Medicine—Reply

Author Affiliations
  • 1Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Baim Institute for Clinical Research, Boston, Massachusetts
  • 2Sanofi, Bridgewater, New Jersey
  • 3Regeneron Pharmaceuticals, Tarrytown, New York
JAMA Cardiol. 2018;3(1):89. doi:10.1001/jamacardio.2017.4353

In Reply We thank Calabrò et al for their very thoughtful letter in response to our study.1 They have correctly noted that the estimates for those requiring proprotein convertase subtilisin/kexin type 9 inhibitors would be further modified by incorporating realistic assumptions on patients unable to tolerate a statin or uptitration of a statin. We have done these analyses and presented preliminary data at the American College of Cardiology Scientific Sessions this year,2 and we plan to submit an article with a more complete analysis soon.

Add or change institution